TA-65 and Aging Associated Microvascular Dysfunction
1 other identifier
interventional
180
0 countries
N/A
Brief Summary
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2027
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 18, 2022
CompletedFirst Posted
Study publicly available on registry
October 28, 2022
CompletedStudy Start
First participant enrolled
January 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
Study Completion
Last participant's last visit for all outcomes
December 31, 2029
May 1, 2026
April 1, 2026
2 years
October 18, 2022
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis
Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME
28 days
Secondary Outcomes (1)
Systemic Blood Pressure
28 days
Study Arms (2)
TA-65
EXPERIMENTALTA-65 (250 U) taken once per day
Placebo
PLACEBO COMPARATORPlacebo taken once per day
Interventions
Eligibility Criteria
You may qualify if:
- Healthy Adults 18 - 35 and 65+ years of age
- Subjects with clinical diagnosis of CAD
You may not qualify if:
- years of age without clinical diagnosis of CAD
- Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr)
- Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
- Heart Failure
- Renal Impairment
- \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
- Type 1 or type 2 diabetes
- Uncontrolled hypertension
- Current tobacco use or within last 6 months
- BMI \> 35
- Hyperlipidemia
- Hypercholesterolemia
- Use of anti-coagulant drugs
- Use of anti-platelet drugs
- Erectile dysfunction medication in the past 6 months
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medical College of Wisconsinlead
- University of Louisvillecollaborator
- Penn State Universitycollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andreas Beyer, Ph.D.
Associate Professor
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Postdoc Fellow
Study Record Dates
First Submitted
October 18, 2022
First Posted
October 28, 2022
Study Start (Estimated)
January 1, 2027
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2029
Last Updated
May 1, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Data available upon record completion